Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2013-12-03 / Front Immunol 2013 Dec;4:417Wilms‘ Tumor Gene 1 (WT1)–loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial
/in Dendritic Cells, Endometrial Cancer, International Publications /von 2013-12-01 / Anticancer Res 2013 Dec;33(12):5495-500
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution